Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Jaclyn A Smith, Michael M Kitt, Alyn H Morice, Surinder S Birring, Lorcan P McGarvey, Mandel R Sher, Yu-Ping Li, Wen-Chi Wu, Zhi Jin Xu, David R Muccino, Anthony P Ford, Jaclyn Smith, Lorcan McGarvey, Surinder Birring, James Hull, Warner W Carr, Alan B Goldsobel, Gary N Gross, John R Holcomb, Iftikhar Hussain
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research